CN113717170A - 雌激素受体调节剂 - Google Patents

雌激素受体调节剂 Download PDF

Info

Publication number
CN113717170A
CN113717170A CN202111035485.4A CN202111035485A CN113717170A CN 113717170 A CN113717170 A CN 113717170A CN 202111035485 A CN202111035485 A CN 202111035485A CN 113717170 A CN113717170 A CN 113717170A
Authority
CN
China
Prior art keywords
optionally substituted
alkyl
group
indol
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111035485.4A
Other languages
English (en)
Chinese (zh)
Inventor
黄琴华
黛博·海伦·斯利
萨伊·盖亚南·海格
查德·丹尼尔·霍普金斯
凯文·杜安·邦克
约瑟夫·罗伯特·平奇曼
拉凯什·库马尔·西特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ricoram Ip Holding Co ltd
Recurium IP Holdings LLC
Original Assignee
Ricoram Ip Holding Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ricoram Ip Holding Co ltd filed Critical Ricoram Ip Holding Co ltd
Publication of CN113717170A publication Critical patent/CN113717170A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/38—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/60—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members
    • C07C2603/62—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members containing three- or four-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202111035485.4A 2016-04-01 2017-03-29 雌激素受体调节剂 Pending CN113717170A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317254P 2016-04-01 2016-04-01
US62/317,254 2016-04-01
CN201780033815.1A CN109311870B (zh) 2016-04-01 2017-03-29 雌激素受体调节剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780033815.1A Division CN109311870B (zh) 2016-04-01 2017-03-29 雌激素受体调节剂

Publications (1)

Publication Number Publication Date
CN113717170A true CN113717170A (zh) 2021-11-30

Family

ID=59966438

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202111035485.4A Pending CN113717170A (zh) 2016-04-01 2017-03-29 雌激素受体调节剂
CN202011582784.5A Pending CN112745316A (zh) 2016-04-01 2017-03-29 雌激素受体调节剂
CN202011582762.9A Active CN112679495B (zh) 2016-04-01 2017-03-29 雌激素受体调节剂
CN201780033815.1A Active CN109311870B (zh) 2016-04-01 2017-03-29 雌激素受体调节剂

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202011582784.5A Pending CN112745316A (zh) 2016-04-01 2017-03-29 雌激素受体调节剂
CN202011582762.9A Active CN112679495B (zh) 2016-04-01 2017-03-29 雌激素受体调节剂
CN201780033815.1A Active CN109311870B (zh) 2016-04-01 2017-03-29 雌激素受体调节剂

Country Status (15)

Country Link
US (5) US20190142811A1 (cg-RX-API-DMAC7.html)
EP (1) EP3442971B1 (cg-RX-API-DMAC7.html)
JP (2) JP6926189B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220071293A (cg-RX-API-DMAC7.html)
CN (4) CN113717170A (cg-RX-API-DMAC7.html)
AR (1) AR108011A1 (cg-RX-API-DMAC7.html)
AU (3) AU2017242027B2 (cg-RX-API-DMAC7.html)
CA (1) CA3017388C (cg-RX-API-DMAC7.html)
ES (1) ES2991862T3 (cg-RX-API-DMAC7.html)
IL (3) IL285318B (cg-RX-API-DMAC7.html)
MX (2) MX392461B (cg-RX-API-DMAC7.html)
RU (1) RU2738646C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201807708SA (cg-RX-API-DMAC7.html)
TW (2) TW202235418A (cg-RX-API-DMAC7.html)
WO (1) WO2017172957A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102479822B1 (ko) 2016-02-05 2022-12-21 인벤티스바이오 엘엘씨 선택적 에스트로겐 수용체 분해제 및 이들의 용도
KR20220071293A (ko) 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
CN107814798B (zh) * 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
WO2018130124A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用
IL272875B2 (en) 2017-09-11 2023-10-01 Recurium Ip Holdings Llc Continuous flow processes for the preparation of bicyclic compounds
EP3709997A1 (en) * 2017-11-16 2020-09-23 Novartis AG Pharmaceutical combination comprising lsz102 and ribociclib
CN114929696A (zh) * 2019-05-24 2022-08-19 浙江海正药业股份有限公司 丙烯酸类衍生物的晶型及其制备方法和用途
KR20220044528A (ko) * 2019-08-06 2022-04-08 리커리엄 아이피 홀딩스, 엘엘씨 돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제
AU2020380211A1 (en) * 2019-11-04 2022-05-19 Recurium Ip Holdings, Llc Salts and forms of an estrogen receptor modulator
CA3165477A1 (en) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
JP2023507797A (ja) * 2019-12-20 2023-02-27 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 組み合わせ
EP4069225A4 (en) * 2019-12-20 2023-12-27 Recurium IP Holdings, LLC COMBINATIONS
IL294067A (en) * 2019-12-20 2022-08-01 Recurium Ip Holdings Llc Combinations
WO2021127042A1 (en) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
WO2021216671A1 (en) * 2020-04-22 2021-10-28 Recurium Ip Holdings, Llc Preparation of an selective estrogen receptor degrader
WO2021253380A1 (en) * 2020-06-19 2021-12-23 InventisBio Co., Ltd. Oral formulations and uses thereof
AU2021343525A1 (en) * 2020-09-20 2023-05-18 Tactogen Inc Advantageous tryptamine compositions for mental disorders or enhancement
WO2022133446A1 (en) * 2020-12-16 2022-06-23 Recurium Ip Holdings, Llc Combinations
EP4267578A4 (en) 2020-12-23 2024-11-20 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS
US12534441B2 (en) 2021-01-15 2026-01-27 Beckley Psytech Limited Tryptamine analogues
WO2023283329A1 (en) * 2021-07-08 2023-01-12 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138706A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating breast cancer
CN105229004A (zh) * 2013-05-28 2016-01-06 阿斯利康(瑞典)有限公司 化合物
CN107428758A (zh) * 2015-11-12 2017-12-01 浙江海正药业股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的用途
CN109362222A (zh) * 2016-02-05 2019-02-19 益方生物科技（上海）有限公司 选择性雌激素受体降解物及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679635B2 (en) 1994-03-11 1997-07-03 Eli Lilly And Company Method for treating 5HT-2B receptor related conditions
GB9604996D0 (en) 1996-03-08 1996-05-08 Black James Foundation Benzodiazonine derivatives
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
JP2005508968A (ja) 2001-10-19 2005-04-07 トランス　テック　ファーマ，インコーポレイテッド ＰＴＰ阻害剤としてのβ−カルボリン誘導体
US8076352B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US20080103164A1 (en) 2004-08-02 2008-05-01 Kristjan Gudmundsson Useful compounds for hpv infection
WO2007002051A1 (en) 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
WO2008002490A2 (en) 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
US20100158858A1 (en) 2007-04-13 2010-06-24 Liangxian Cao Administration of carboline derivatives useful in the treatment of cancer and other diseases
DE102007028515A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
TW201028414A (en) 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
WO2010107485A1 (en) 2009-03-17 2010-09-23 The Trustees Of Columbia University In The City Of New York E3 ligase inhibitors
MX373926B (es) * 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
RU2540330C2 (ru) * 2009-07-28 2015-02-10 Оно Фармасьютикал Ко., Лтд. Бициклическое соединение и его применение для медицинских целей
WO2011088025A1 (en) 2010-01-15 2011-07-21 Merck Sharp & Dohme Corp. Oxadiazole beta carboline derivatives as antidiabetic compounds
NZ602266A (en) * 2010-02-11 2014-05-30 Bristol Myers Squibb Co Macrocycles as factor xia inhibitors
WO2011103487A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
JP5835236B2 (ja) * 2011-01-27 2015-12-24 小野薬品工業株式会社 二環式化合物およびその医薬用途
CN102432608B (zh) 2011-11-01 2013-04-17 浙江大学 手性螺环磷酸催化合成光学活性四氢-β-咔啉衍生物的方法
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
MX353578B (es) * 2011-12-31 2018-01-19 Beigene Ltd Dihidrodiazpinocarbazolonas tetra o penta-ciclicas fusionadas como inhibidores de poli (adp-ribosa) polimerasa (parp).
CA2863413A1 (en) * 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
US9499538B2 (en) 2012-03-20 2016-11-22 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
LT2872482T (lt) 2012-07-13 2020-12-28 Oncternal Therapeutics, Inc. Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
ES2671516T3 (es) 2013-02-19 2018-06-06 Novartis Ag Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
MX2015011132A (es) 2013-03-14 2015-11-30 Seragon Pharmaceuticals Inc Moduladores policiclicos del receptor de estrogenos y sus usos.
EP3089747A1 (en) 2013-12-06 2016-11-09 F. Hoffmann-La Roche AG Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
CN104693211A (zh) 2013-12-10 2015-06-10 南京明德新药研发股份有限公司 作为抗病毒剂的咪唑衍生物及其制药用途
TW201613891A (en) * 2014-02-12 2016-04-16 Eolas Therapeutics Inc Substituted prolines / piperidines as orexin receptor antagonists
WO2015171527A1 (en) 2014-05-05 2015-11-12 Global Blood Therapeutics, Inc. Pyrazolopyridine pyrazolopyrimidine and related compounds
CA2948077A1 (en) 2014-05-16 2015-11-19 Actelion Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives
MX388871B (es) 2014-06-27 2025-03-20 Nogra Pharma Ltd Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
WO2016054971A1 (zh) 2014-10-09 2016-04-14 南京明德新药研发股份有限公司 羟基嘌呤类化合物及其应用
CN107709290B (zh) 2015-04-21 2023-02-28 Gtx公司 选择性雄激素受体降解剂(sard)配体和其使用方法
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10087191B2 (en) * 2015-06-16 2018-10-02 Jiangsu Hengrui Medicine Co., Ltd. Piperidine derivative and preparation method and pharmaceutical use thereof
KR20220071293A (ko) * 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
CN109310664A (zh) 2016-06-10 2019-02-05 田纳西大学研究基金会 选择性雄激素受体降解剂(sard)配体和其使用方法
WO2018001232A1 (zh) * 2016-06-29 2018-01-04 浙江海正药业股份有限公司 丙烯酸类衍生物及其制备方法和其在医药上的用途
JP7050770B2 (ja) * 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
WO2018130124A1 (zh) 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138706A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating breast cancer
CN105229004A (zh) * 2013-05-28 2016-01-06 阿斯利康(瑞典)有限公司 化合物
CN107428758A (zh) * 2015-11-12 2017-12-01 浙江海正药业股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的用途
CN109362222A (zh) * 2016-02-05 2019-02-19 益方生物科技（上海）有限公司 选择性雌激素受体降解物及其用途

Also Published As

Publication number Publication date
BR112018070161A2 (pt) 2019-02-12
IL285318A (en) 2021-09-30
IL295050A (en) 2022-09-01
RU2018132037A (ru) 2020-05-12
AU2017242027B2 (en) 2020-10-08
US20200261428A1 (en) 2020-08-20
JP2021176911A (ja) 2021-11-11
CA3017388A1 (en) 2017-10-05
RU2738646C2 (ru) 2020-12-15
WO2017172957A1 (en) 2017-10-05
MX2018011419A (es) 2019-06-06
AU2020294196A1 (en) 2021-01-28
KR102401841B1 (ko) 2022-05-25
AU2022204025A1 (en) 2022-06-30
US11065233B2 (en) 2021-07-20
CN109311870A (zh) 2019-02-05
IL261654B (en) 2021-08-31
CN112679495B (zh) 2023-03-28
KR20190002478A (ko) 2019-01-08
US20200261429A1 (en) 2020-08-20
IL261654A (en) 2018-10-31
AU2020294196B2 (en) 2022-06-16
MX2022005780A (es) 2022-06-09
KR20220071293A (ko) 2022-05-31
RU2018132037A3 (cg-RX-API-DMAC7.html) 2020-05-15
US20190142811A1 (en) 2019-05-16
EP3442971B1 (en) 2024-09-25
US10959989B2 (en) 2021-03-30
SG11201807708SA (en) 2018-10-30
TW202235418A (zh) 2022-09-16
EP3442971A1 (en) 2019-02-20
MX392461B (es) 2025-03-11
IL285318B (en) 2022-09-01
CN109311870B (zh) 2021-09-21
TWI746535B (zh) 2021-11-21
US20210330651A1 (en) 2021-10-28
US20200261430A1 (en) 2020-08-20
JP2019515026A (ja) 2019-06-06
ES2991862T3 (es) 2024-12-05
TW201736334A (zh) 2017-10-16
EP3442971C0 (en) 2024-09-25
JP6926189B2 (ja) 2021-08-25
EP3442971A4 (en) 2020-01-01
AR108011A1 (es) 2018-07-04
AU2017242027A1 (en) 2018-10-11
CN112679495A (zh) 2021-04-20
CA3017388C (en) 2024-03-12
CN112745316A (zh) 2021-05-04
US11065234B2 (en) 2021-07-20

Similar Documents

Publication Publication Date Title
CN109311870B (zh) 雌激素受体调节剂
WO2021208918A1 (zh) 作为egfr抑制剂的三环化合物
JP2021500334A (ja) Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物、その塩、及びそれらの合成方法
CN113874367B (zh) 吲唑类衍生物、其制备方法及其在医药上的应用
HK40064960A (en) Estrogen receptor modulators
WO2025067239A1 (zh) 驱动蛋白kif18a抑制剂及其应用
HK40052769A (en) Estrogen receptor modulators
KR20250008116A (ko) 이미다조피리다진 치환 벤젠 고리 유도체, 제조방법, 약학 조성물 및 용도
CN107235960A (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
BR112018070161B1 (pt) Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso dos mesmos e método para inibir o crescimento de célula
HK40064838B (zh) 吲唑类衍生物、其制备方法及其在医药上的应用
HK40004087A (en) Estrogen receptor modulators
HK40004087B (en) Estrogen receptor modulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40064960

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211130

WD01 Invention patent application deemed withdrawn after publication